RANK/RANK-L/OPG in Patients with Bone Metastases Treated with Anticancer Agents and Zoledronic Acid: A Prospective Study

Role of RANK, RANKL, OPG, and CXCR4 Tissue Markers in Predicting Bone Metastases in Breast Cancer Patients

(2011) Toni Ibrahim et al.   Clinical Breast Cancer

The Role of CXCR4 in the Prediction of Bone Metastases from Breast Cancer: A Pilot Study

(2011) Emanuele Sacanna et al.   ONCOLOGY

Biomarker alterations with metronomic use of low-dose zoledronic acid for breast cancer patients with bone metastases and potential clinical significance

(2010) Xinmin Zhao et al.   BREAST CANCER RESEARCH AND TREATMENT

Markers of bone remodeling and skeletal morbidity in patients with solid tumors metastatic to the skeleton receiving the biphosphonate zoledronic acid

(2010) Giannis Mountzios et al.   Translational Research

Implications of Serum Bone Turnover Markers in Prostate Cancer Patients With Bone Metastasis

(2010) Naoto Kamiya et al.   UROLOGY

Zoledronic acid and skeletal complications in patients with solid tumors and bone metastases

(2008) Hind T. Hatoum et al.   CANCER

Bone markers and their prognostic value in metastatic bone disease: Clinical evidence and future directions

(2008) Robert Coleman et al.   CANCER TREATMENT REVIEWS

Osteonecrosis of the Jaw in Patients with Bone Metastases Treated with Bisphosphonates: A Retrospective Study

(2008) T. Ibrahim et al.   ONCOLOGIST